354 related articles for article (PubMed ID: 33283236)
1. Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer.
Tsuchida K; Sato T; Aoyama T; Atsumi Y; Kano K; Maezawa Y; Kazama K; Numata M; Yamada T; Tamagawa H; Murakami H; Oshima T; Saeki H; Cho H; Yukawa N; Yamamoto Y; Masuda M; Rino Y
Jpn J Clin Oncol; 2021 Mar; 51(3):371-378. PubMed ID: 33283236
[TBL] [Abstract][Full Text] [Related]
2. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704).
Kurokawa Y; Doki Y; Kitabayashi R; Yoshikawa T; Nomura T; Tsuji K; Goto M; Cho H; Hihara J; Hiki N; Nunobe S; Mizusawa J; Boku N; Terashima M
Gastric Cancer; 2024 Mar; 27(2):366-374. PubMed ID: 38180622
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Molecular Mechanisms of S-1, Docetaxel and Cisplatin in Gastric Cancer with a History of Helicobacter Pylori Infection.
Kashani SF; Abedini Z; Darehshouri AF; Jazi K; Bereimipour A; Malekraeisi MA; Javanshir HT; Mahmoodzadeh H; Hadjilooei F
Mol Biotechnol; 2024 May; 66(5):1303-1313. PubMed ID: 38273052
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902).
Kawase T; Imamura H; Kawabata R; Matsuyama J; Nishikawa K; Yanagihara K; Yamamoto K; Hoki N; Kawada J; Kawakami H; Sakai D; Kurokawa Y; Shimokawa T; Satoh T
Int J Clin Oncol; 2024 Feb; 29(2):134-141. PubMed ID: 38227090
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y
Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis.
Tang C; Feng W; Bao Y; Chen C
Onco Targets Ther; 2020; 13():12661-12666. PubMed ID: 33324076
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Shimokawa T; Yamada K; Tanaka H; Kubota K; Takiguchi Y; Kishi K; Saito H; Hosomi Y; Kato T; Harada D; Otani S; Kasai T; Nakamura Y; Misumi T; Yamanaka T; Okamoto H
Cancer Med; 2021 Jan; 10(2):626-633. PubMed ID: 33319495
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes Following Combination of First-Line Platinum-Based Chemotherapy with S-1 in Patients with Advanced Gastric Cancer.
Koumarianou A; Ntavatzikos A; Vallilas C; Kampoli K; Kakoseou Z; Karamouzis MV
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33333977
[TBL] [Abstract][Full Text] [Related]
10. Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.
Yamada Y; Muro K; Takahashi K; Baba H; Komatsu Y; Satoh T; Goto M; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Takenaka N; Hirooka T; Sugihara K
Glob Health Med; 2020 Aug; 2(4):240-246. PubMed ID: 33330814
[TBL] [Abstract][Full Text] [Related]
11. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Crabb SJ; Griffiths G; Marwood E; Dunkley D; Downs N; Martin K; Light M; Northey J; Wilding S; Whitehead A; Shaw E; Birtle AJ; Bahl A; Elliott T; Westbury C; Sundar S; Robinson A; Jagdev S; Kumar S; Rooney C; Salinas-Souza C; Stephens C; Khoo V; Jones RJ
J Clin Oncol; 2021 Jan; 39(3):190-201. PubMed ID: 33326257
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lu S; Wang J; Cheng Y; Mok T; Chang J; Zhang L; Feng J; Tu HY; Wu L; Zhang Y; Luft A; Zhou JY; Ma Z; Lu Y; Hu C; Shi Y; Ying K; Zhong H; Poddubskaya E; Soo RA; Chia YH; Li A; Li A; Wu YL
Lung Cancer; 2021 Feb; 152():7-14. PubMed ID: 33321441
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
14. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
Minatogawa H; Izawa N; Kawaguchi T; Miyaji T; Shimomura K; Kazunori H; Iihara H; Ohno Y; Inada Y; Arioka H; Morita H; Hida N; Sugawara M; Katada C; Nawata S; Ishida H; Tsuboya A; Tsuda T; Yamaguchi T; Nakajima TE
BMJ Open; 2020 Dec; 10(12):e041737. PubMed ID: 33334838
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Nishio M; Barlesi F; West H; Ball S; Bordoni R; Cobo M; Longeras PD; Goldschmidt J; Novello S; Orlandi F; Sanborn RE; Szalai Z; Ursol G; Mendus D; Wang L; Wen X; McCleland M; Hoang T; Phan S; Socinski MA
J Thorac Oncol; 2021 Apr; 16(4):653-664. PubMed ID: 33333328
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
[TBL] [Abstract][Full Text] [Related]
17. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
van Brummelen EMJ; Huijberts S; van Herpen C; Desar I; Opdam F; van Geel R; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema A; Beijnen J; Bernards R; Schellens J
Oncologist; 2021 Apr; 26(4):290-e545. PubMed ID: 33296125
[TBL] [Abstract][Full Text] [Related]
19. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
Moriwaki T; Gosho M; Sugaya A; Yamada T; Yamamoto Y; Hyodo I
Cancer Res Treat; 2021 Jul; 53(3):703-713. PubMed ID: 33285056
[TBL] [Abstract][Full Text] [Related]
20. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
Dimopoulos M; Sanz RG; Lee HP; Trneny M; Varettoni M; Opat S; D'Sa S; Owen RG; Cull G; Mulligan S; Czyz J; Castillo JJ; Motta M; Siddiqi T; Gironella Mesa M; Granell Gorrochategui M; Talaulikar D; Zinzani PL; Askari E; Grosicki S; Oriol A; Rule S; Kloczko J; Tedeschi A; Buske C; Leblond V; Trotman J; Chan WY; Michel J; Schneider J; Tan Z; Cohen A; Huang J; Tam CS
Blood Adv; 2020 Dec; 4(23):6009-6018. PubMed ID: 33284944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
